Keyphrases
Enterotoxigenic Escherichia Coli
73%
Placebo
69%
Human Challenge Model
51%
Conjugate Vaccine
51%
Human Challenge Studies
51%
Vaccination
43%
Severe Diarrhea
41%
Escherichia Coli Strains
37%
Shigellosis
35%
Colony Forming Units
34%
Immune Response
33%
Diarrhea
32%
Shigella
30%
Shigella Flexneri 2a
30%
Immunization
29%
Correlates of Protection
29%
Stakeholder Participation
25%
COVID-19 Risk
25%
Randomized Trial
25%
Oral Vaccine
25%
Community-based nutrition
25%
Vaccine Candidate
25%
Protection Efficiency
25%
Response Characterisation
25%
Nutrition Intervention
25%
Clinical Correlation
25%
Local Stakeholders
25%
Hyperimmune Serum
25%
Vaccine Analysis
25%
Serum Antibody
25%
Bovine Serum
25%
Natural Infection
25%
Clinical Efficacy
25%
Shigella Flexneri
25%
Previous Infection
25%
Enterotoxigenic E. Coli
25%
Oral Delivery
25%
Active Participation
21%
Vaccinees
21%
Lipopolysaccharide
20%
Serum IgG
19%
Overnight Fast
18%
Moderate-to-severe Diarrhea
16%
Escherichia Coli Infections
15%
Hybrid Immunity
13%
IgG Response
13%
Whole Cell
12%
Severe Disease
12%
Disease Severity
12%
Protective Efficacy
11%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Infection
75%
Shigella
64%
Diarrhea
60%
Placebo
58%
Shigellosis
57%
Escherichia coli
51%
Vaccination Policy
50%
Enterotoxigenic Escherichia Coli
47%
Disease Severity
37%
Lipopolysaccharide
34%
Shigella flexneri
29%
Immunoglobulin A
29%
Oral Vaccine
25%
Vaccine Development
24%
Physical Disease by Body Function
20%
Exotoxin
17%
Polysaccharide
17%
Pseudomonas aeruginosa
17%
Shigella Vaccine
17%
Antimicrobial Resistance
12%
Bacterium Antibody
12%
Infectious Agent
12%
Intestine Infection
12%
Symptom
9%
Loose Feces
9%
Vaccine
8%
Dysentery
8%
Adverse Event
7%
Abdominal Pain
5%
Anorexia
5%
Abdominal Cramp
5%
Headache
5%
Immunology and Microbiology
Vaccine Efficacy
73%
Enterotoxigenic Escherichia Coli
51%
Immune Response
38%
Colony Forming Unit S
35%
Shigella
32%
Vaccination Policy
32%
Escherichia coli
29%
COVID-19
25%
Shigella flexneri
25%
Antibody Blood Level
25%
Hybrid Immunity
19%
Monospecific Antibody
17%
Whole Cell
12%
Immunoglobulin A
12%
Inoculum
7%
Shigella Vaccine
6%
Memory B Cell
6%
Pseudomonas aeruginosa
6%
Exotoxin
6%
Infectious Agent
6%
Bacterium Antibody
6%
Antimicrobial Resistance
6%
B Cell
6%
Sample Size
5%